The Gene therapy market was valued $2.26 Bn in 2020 and is expected grow at a CAGR of xx%.
Market Introduction and Overview

Gene therapy and novel therapeutics applying gene therapy-based techniques have experienced a drastic advance in the past 10 years. Clinically functional gene therapies are established now for certain diseases, and many other promising therapeutics have been developed, with such a trend being most noticeable in the field of haematological diseases. Recent advances in gene therapy and gene therapy-based approaches have been quite considerable, which include delivery vectors, gene engineering technologies and application to chimeric antigen receptor (CAR) T cell therapy.

These advances have realized many of the unmet promises of gene therapy for genetic diseases. Furthermore, the application of gene therapy technologies to non-hereditary diseases such as malignancies has recently started to display positive outcomes, such as with CAR-T cell therapy and the oncolytic virus. The ongoing advances in gene therapy is boosting the market growth.

Gene therapy has been an active area of research for at least the past two decades. As of January 28, 2018, ten gene therapy products have been approved for marketing in at least one country in the world. Recent predictions for the near future range from 12 to 14 new gene therapies submitted for approval in the next couple of years, to around 40 new therapies approved by the end of 2022.
The gene therapy field is growing at an unprecedented pace. Healthcare giants are focusing on establishments of own products and platforms which will propel their presence in the market. Strengthening internal capabilities, external strategic collaborations and technology acquisitions by key market players are expanding the market.

On December 9 2020, Bayer recently announced the launch of a cell and gene therapy platform (C&GT) within its pharmaceutical division. The platform will further consolidate company’s emerging leadership in the cell and gene therapy field and transform its overall business. Launching of new pipelines by top players is propelling the gene therapy market.

The report contains detailed analysis of Strengths, Weakness and opportunities of the key players operating in Gene Therapy Market. It also provides information on current market trends, competitive ranking analysis, regional bifurcation, turnover forecasts, industry drivers and the key challenges.
The report has profiled more than twenty key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analysing the market and estimation the size of the same. The growing healthcare infrastructure in each region is different and focus is given on availability of advanced technology and new techniques.

Global-Gene-Therapy-Market.png
Gene therapy market Segment Analysis

By Indication, the spinal muscular atrophy segment led the market in 2020 with a highest revenue share of 41%. The large B-cell lymphoma segment is expected to grow significantly in the forecast period. SMA is a hereditary disease that causes weakness and muscle wasting because patients lose lower motor neurons (nerve cells) that control movement. SPINRAZA is the first therapy approved to treat infants, children and adults with spinal muscular atrophy (SMA) and is approved in more than 50 countries. As of December 31, 2019, more than 10,000 individuals have been treated with SPINRAZA. On August 7 2020, Roche received the approval for Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA. This is the second drug and the first oral drug approved to treat this disease.

By vector type, Adeno-associated virus (AAV) vector segment held the largest market share of 43% in 2020, Owing to the vector’s low immunogenicity, safety and long-term transient expression. Investigators from Dyno Therapeutics, Google Research, and partners have reported successfully using artificial intelligence to generate an unprecedented diversity of adeno-associated virus (AAV) capsids, in order to identify functional variants capable of evading the immune system, a key hurdle to wider use of gene therapy.

On the other hand, lentiviruses are anticipated to emerge as the fastest-growing vector type segment from 2021 to 2026. This can be attributed to the rising investments by companies and research institutes in this vector type, post-approval of Zynteglo in 2019 and Kymriah in 2017.

To know about the Research Methodology :- Request Free Sample Report
Gene therapy market Regional Insights

North America accounted for the largest market share of 55% in 2020 and is expected to grow a CAGR of xx% in the forecast period. Growth in insurance coverage, presence of centers and institutes engaged in R&D and government funding are up surging the North American gene therapy market. Well-established healthcare infrastructure, ease of availability is also a key driver affecting the market growth. Investments by key players in this field has boosted the market growth. Rising adoption of technologically advanced diagnostic imaging systems for gene therapy is rapidly growing the market. Moreover, the approval of Zolgensma in 2019 significantly favoured the US market.
Asia Pacific is also expected to witness significant growth during the forecast period due to rising health care expenditures. The allocation of a large amount of healthcare expenditure for hospitals and dispensing medicines to the elderly is expected drive the market demand.

For More Information Visit :

https://www.maximizemarketresearch.com/market-report/global-gene-therapy-market/85074/


Scope of the Gene therapy market: Inquire before Buying

Gene therapy market, By Region

• North America
• Europe
• South America
• MEA
• Asia Pacific
Key Players Operating in the Global Gene Therapy Market

• REGENXBIO, Inc.
• Bayer
• Oxford BioMedica plc
• Dimension Therapeutics, Inc.
• Bristol-Myers Squibb Company
• SANOFI
• Applied Genetic Technologies Corp
• F. Hoffmann-La Roche Ltd.
• Bluebird Bio, Inc.
• Novartis AG
• Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
• UniQure N.V.
• Shire Plc;
• Cellectis S.A.
• Sangamo Therapeutics, Inc.
• Orchard Therapeutics
• Gilead Lifesciences, Inc.
• Benitec Biopharma Ltd.
• Sibiono GeneTech Co., Ltd.
• Shanghai Sunway Biotech Co., Ltd
• Gensight Biologics S.A.
• Transgene
• Calimmune, Inc
• Epeius Biotechnologies Corp
• Astellas Pharma, Inc
• American Gene Technologies
• BioMarin Pharmaceuticals, Inc.
• Human Stem Cell Institute
• Spark Therapeutics LLC
• GlaxoSmithKline
• Voyager Therapeutics

The report also helps in understanding Global Gene Therapy Market dynamics, structure by analysing the market segments and project the Global Gene Therapy Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Gene Therapy Market make the report investor’s guide.

 

This Report Is Submitted By : Maximize Market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

 

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.